Clinical trials
Unresectable Solid Tumor clinical trials
Below are recruiting unresectable solid tumor clinical trials, each written for real people, not researchers. We’re tracking 428 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06822998RecruitingEarly Phase 1
HF50 for HER-2 positive and low-expression advanced tumors
This trial tests a new drug, HF50, in people with advanced solid tumors that are HER-2 positive or have low HER-2 levels. It may be an option if standard treatments have stopped working or are not tolerated.
Chengdu, SichuanAges 18–75 - NCT07524348RecruitingPhase 1
Safety Study of E303 Drug in Advanced Solid Tumors
This early-stage trial tests whether a new drug called E303 is safe for patients with advanced solid cancers (tumors that have spread or returned). Researchers want to find the right dose and watch for side effects.
Scottsdale, ArizonaAges 18 years+ - NCT05836948RecruitingPhase 1
Testing SHR-9839 for advanced solid tumors
This Phase 1 trial studies SHR-9839, a new injection medicine, for people with advanced solid tumors that can’t be removed by surgery and have returned or stopped responding to standard care. It mainly aims to find a safe dose and see early signs of whether the treatment can work.
Hangzhou, ZhejiangAges 18–70 - NCT06304571RecruitingPhase 1
Study of HC006 for advanced solid tumors
This study tests a new drug called HC006 for advanced solid tumors that no longer respond to standard treatments. It aims to find a safe dose and see if it helps shrink tumors.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06238401RecruitingPhase 1
Testing ACR246 for advanced solid tumors
This trial tests a new drug called ACR246 for people with advanced solid tumors that have not responded to standard treatments. The study aims to find the safest dose and see if the drug can shrink tumors.
Beijing, Beijing MunicipalityAges 18–75 - NCT07639047RecruitingPhase 1
Testing AN8025 in Advanced Solid Cancers
This early-stage trial tests a new drug called AN8025 in people with advanced solid tumors (cancers that started in organs or tissues). The study aims to find the right dose and see if it helps patients whose cancers have grown despite other treatments.
Nedlands, Western AustraliaAges 18 years+ - NCT05725291RecruitingPhase 1
Early study drug for advanced cancers after other treatments
This Phase 1 trial tests AMT-116, an investigational medicine, in people with advanced solid cancers that can’t be removed by surgery and have gotten worse after standard treatment. It looks for the best safe dose and early signs the treatment may shrink tumors or slow growth.
Denver, ColoradoAges 18 years+ - NCT07387068RecruitingPhase 1
Testing GEN1079 for advanced solid tumors
This trial tests an experimental drug called GEN1079 for people with advanced solid tumors that have spread or cannot be removed. The goal is to see if it's safe and if it helps shrink tumors.
New Haven, ConnecticutAges 18 years+ - NCT07477743RecruitingPhase 1
Study of a new drug combo for advanced solid tumors
This trial tests a new combination treatment (HC010) for people with advanced solid tumors that have spread or cannot be removed by surgery. It aims to see if the drug is safe and effective.
BeijingAges 18–75 - NCT07067567RecruitingPhase 1
Study of AK146D1 injection for advanced solid tumors
This trial tests a new drug called AK146D1 for people with advanced solid tumors that have not responded to standard treatments or no longer work. The goal is to see if it is safe and effective.
Guangzhou, GuangdongAges 18–75 - NCT07165067RecruitingPhase 1
Testing AP601 for advanced solid tumors that have not responded to treatment
This trial tests a new drug called AP601 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective, and it targets CD73 and CD137 pathways to help your immune system fight cancer.
Waratah, New South WalesAges 18 years+ - NCT06066424RecruitingPhase 1
TROP2-targeted NK cells for advanced solid tumors
This trial tests a new type of cell therapy using your own immune cells (NK cells) that are specially engineered to attack cancer cells that have a protein called TROP2. It is for people with advanced solid tumors that have not responded to standard treatments.
Houston, TexasAges 18 years+ - NCT06669975RecruitingPhase 1/Phase 2
Testing AP402 for her2-positive advanced solid tumors
This trial tests an experimental drug called AP402 for people with HER2-positive solid tumors that have spread or cannot be removed by surgery, and who have no standard treatment options left. The goal is to see if AP402 can shrink tumors or slow their growth.
Macquarie, New South WalesAges 18 years+ - NCT06741644RecruitingPhase 1/Phase 2
CS2009 for advanced solid tumors
This trial tests a new drug called CS2009 for people with advanced solid tumors that haven't responded to other treatments. It aims to see if the drug is safe and effective.
Los Angeles, CaliforniaAges 18 years+ - NCT07077434RecruitingPhase 1
Study of Navlimetostat for advanced solid tumors with specific gene change
This trial tests a new drug, Navlimetostat (BMS-986504), for people with advanced solid tumors that have a specific genetic change called MTAP deletion or loss. It looks at safety, side effects, and how the drug works in the body.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07182591RecruitingPhase 1
Study of DS5361b for advanced solid tumors with high TMB or MSI
This study tests a new drug (DS5361b) for people with advanced solid tumors that have high genetic instability (TMB-H or MSI-H). It aims to see if the drug can shrink tumors or slow their growth.
Sarasota, FloridaAges 18 years+ - NCT07359066RecruitingPhase 1/Phase 2
SPR1020 for advanced solid tumors with DNA repair defects
This trial tests an experimental drug (SPR1020) for people with advanced solid tumors that have not responded to standard treatments, especially those with BRCA or related gene mutations. The drug is taken by mouth and the study aims to find the right dose and see if it helps shrink tumors.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06233942RecruitingPhase 1
Testing a new drug for advanced solid tumors
This early-phase trial tests a new drug called BG-C9074, either alone or with other cancer treatments, for people with certain advanced solid tumors that have not responded to standard therapy. The goal is to see if it is safe and effective.
Los Angeles, CaliforniaAges 18 years+ - NCT05687682RecruitingPhase 1
AM-928 infusion safety study for advanced solid tumors
This Phase 1 trial tests how safe AM-928 is when given through an IV infusion to people with advanced solid cancers that can’t be removed by surgery and have stopped responding to standard treatments. It may help doctors learn the safest dose and whether the drug causes side effects worth watching.
TaipeiAges 18 years+ - NCT06804824RecruitingPhase 1
Testing a new drug for advanced solid tumors with certain gene changes
This study tests an experimental drug called VVD-159642 in people with advanced solid tumors that have specific genetic changes (RAS or EGFR alterations, or HER2 overexpression). The goal is to see if the drug is safe and tolerable.
Grand Rapids, MichiganAges 18 years+ - NCT06589596RecruitingPhase 1
Study of BGB-58067 for advanced solid tumors
This trial tests an experimental drug called BGB-58067, either alone or with other cancer treatments, for people with advanced solid tumors that have stopped responding to standard therapy. It may be an option if you have a specific genetic change (loss of MTAP) in your tumor.
Los Angeles, CaliforniaAges 18 years+ - NCT06514651RecruitingPhase 1
MAQ-001 for advanced solid tumors after PD-1/PD-L1 therapy
This study tests a new experimental drug called MAQ-001 in people with advanced solid tumors or lymphomas that have already been treated with a PD-1/PD-L1 checkpoint inhibitor. The goal is to see if MAQ-001 can shrink or control the cancer when other treatments are no longer working.
LyonAges 18 years+ - NCT06929663RecruitingPhase 1
Study of AK146D1 for advanced solid tumors
This study tests an experimental drug (AK146D1) for people with advanced solid tumors that are no longer responding to standard treatments. The goal is to see if it is safe and effective.
Sydney, New South WalesAges 18–75 - NCT05684965RecruitingPhase 1/Phase 2
Study drug for advanced solid cancers after standard treatments
This Phase 1/2 trial tests XTX301, a study treatment, in people with advanced solid tumors (cancers) that have already been treated and are not controlled by standard options. It may help if your cancer matches one of the study groups and you meet safety and test-tissue requirements.
Sacramento, CaliforniaAges 18 years+
Hear when a new Unresectable Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for unresectable solid tumor?
- Yes. Clin2 currently lists 428 recruiting unresectable solid tumor studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a unresectable solid tumor trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a unresectable solid tumor trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.